StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
7097.T$2950.00+2.38%
Fair $2950.00+0.0%

7097.T

SAKURASAKU PLUS,Co.,Ltd.

Healthcare / Medical Care FacilitiesTokyo

$2950.00

+69.00 (+2.38%)

Fairly Valued+0.0%Fair Value $2950.00Fund rank 22/100 · Data gapFallback financials|
SA 58/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-1.5B · quality 33.7/100

Data gap 22/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 5/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

58/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 7097.TLocal privado en este navegador · SAKURASAKU PLUS,Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$13.1B

P/E

17.4x

↓

EV/EBITDA

14.6x

↑

ROE

11.5%

↑

Gross Margin

13.4%

↓

Debt/Equity

0.85

↑
52-Week Range$2950
$2120$3350

TradingView lightweight chart

7097.T price, volumen y niveles de valoración

Último $2,974Periodo +8.7%
Fair value: $2,950

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2024 · 3 años de histórico normalizado

Revenue CAGR

+19.8%

FCF CAGR

—

FCF margin

12.0%

FCF / Net income

3.42x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $17.21B · net income $607.0M · FCF $2.07B

2021-FY → 2024-FY

Gross margin

13.4%-2.5% pts

Operating margin

4.5%-0.1% pts

Net margin

3.5%-6.0% pts

FCF margin

12.0%+17.1% pts
MetricTTM
2024
2023
2022
2021
Income Statement
Revenue$17.21B$17.21B$13.84B$11.99B$10.00B
Net Income$607.0M$607.0M$325.0M$365.0M$956.0M
EBITDA$1.13B$1.13B$991.0M$1.51B$2.08B
EPS133.10133.1069.8677.45—
Gross Margin13.4%13.4%11.8%10.8%15.9%
Operating Margin4.5%4.5%2.3%0.2%4.6%
Net Margin3.5%3.5%2.3%3.0%9.6%
Balance Sheet
Debt/Equity0.850.851.141.000.79
Current Ratio1.491.49———
Cash Flow
Free Cash Flow$2.07B$2.07B$-1.47B$-1.92B$-507.0M
Returns
ROE11.5%11.5%6.6%7.9%22.6%
Valuation
P/E17.3717.379.5814.58—
EV/EBITDA14.6014.608.025.695.34
P/B2.552.550.631.152.10
Growth & Yield
Revenue Growth24.3%24.3%15.4%19.9%—
EPS Growth90.5%90.5%-9.8%——
Dividend Yield0.9%0.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

25.3%

muy exigente

EPS terminal req.

$261.76

Spread vs growth

65.2%

5Y implied EPS CAGR

18.9%

exigente

EPS terminal req.

$316.73

Spread vs growth

71.6%

10Y implied EPS CAGR

14.4%

razonable

EPS terminal req.

$510.10

Spread vs growth

76.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +41.2%

Total return

+41.2%

Start / end P/E

30.3x → 22.3x

EPS bridge

69.86 → 133.10

Residual

-23.9%

EPS growth+90.5%
Multiple rerating-26.4%
Dividend+0.9%
Residual / FX / buybacks / cross-term-23.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.